The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial
| Autor: | Philip Tata, Andrew Gumley, John Norrie, Stephen Palmer, Kate Davidson, Peter Tyrer, Helen Seivewright, Heather Murray |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Suicide Prevention medicine.medical_specialty Cost effectiveness medicine.medical_treatment Cost-Benefit Analysis Anxiety Article law.invention Quality of life (healthcare) Randomized controlled trial Ambulatory care law Borderline Personality Disorder Outpatients medicine Ambulatory Care Humans Psychiatry Borderline personality disorder Aged Cognitive Behavioral Therapy Reproducibility of Results Middle Aged medicine.disease Quality-adjusted life year Psychiatry and Mental health Clinical Psychology Treatment Outcome Cognitive therapy Female Quality-Adjusted Life Years medicine.symptom Psychology Self-Injurious Behavior Social Adjustment Clinical psychology |
| Zdroj: | Journal of personality disorders. 20(5) |
| ISSN: | 0885-579X |
| Popis: | Borderline personality disorder places a significant burden on healthcare providers and other agencies. This study evaluated the cost-effectiveness of cognitive behavior therapy plus treatment as usual compared to treatment as usual alone for patients with borderline personality disorder. The economic analysis was conducted alongside a multi-center, randomized controlled trial. The costs of primary and secondary healthcare utilization, alongside the wider economic costs, were estimated from medical records and patient self-report. The primary outcome measure used was the quality-adjusted life year (QALY), assessed using EuroQol. On average, total costs per patient in the cognitive behavior therapy group were lower than patients receiving usual care alone (-689 pounds sterling), although this group also reported a lower quality of life (-0.11 QALYs). These differences were small and did not approach conventional levels of statistical significance. The use of cognitive therapy for borderline personality disorder does not appear to demonstrate any significant cost-effective advantage based on the results of this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|